- Home
- NRSN vs BRNS Comparison
NRSN vs BRNS Comparison
Compare NRSN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRSN | BRNS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | Israel | United States |
| Employees | 16 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 24.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRSN | BRNS |
|---|---|---|
| Price | $0.60 | $0.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.50 | $4.00 |
| AVG Volume (30 Days) | ★ 160.7K | 39.4K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $583.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $0.51 |
| 52 Week High | $2.09 | $1.83 |
Technical Indicators
Market Signals| Indicator | NRSN | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 27.20 | 44.33 |
| Support Level | N/A | $0.56 |
| Resistance Level | $0.74 | $0.62 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 13.19 | 34.67 |
Price Performance
Historical ComparisonAbout NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.